Pharmaceuticals, Biotechnology and Life Sciences
Sanofi has appointed Bill Sibold, a current head of Sanofi Genzyme’s Global Multiple Sclerosis, Oncology and Immunology organization, as Executive Vice President Sanofi Genzyme and member of the Executive Committee, effective July 1, 2017.
Sosei Group Corporation’s subsidiary Heptares Therapeutics got milestone payment from AstraZeneca for working together on an immuno-oncology project.
Abzena, a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, will initiate a placing to raise approximately £25 million to expand further its service offering, capacity and capabilities.
JHL Biotech said Wednesday its Clinical Trial Application (CTA) for use of its first product in pipleine, JHL1101 in Phase 1 and Phase 3 clinical trials in Non-Hodgkin’s Lymphoma patients has been accepted by the China Food and Drug Administration (CFDA).
BD (Becton, Dickinson and Company), a medical technology company, has completed the acquisition of Israeli-based Caesarea Medical Electronics (CME), a global infusion pump systems manufacturer.
According to the report, the global market radiopharmaceuticals were valued at nearly $5.1 billion and $5.7 billion in 2014 and 2015, respectively.
The U.S. FDA will review a supplemental New Drug Application for Janssen’s Imbruvica for chronic graft-versus-host-disease after failed certain therapies.
Cannabics Pharmaceuticals has received the final report of the research held in the Technion Israel Institute of Technology, in which the antitumor activity of cannabinoids was reflected in several types of cancer.
Creso Pharma has appointed pharmaceutical and biotech industry professional David Russell as its Chief Operating Officer.
Galapagos NV announced on Tuesday three new Phase 2 Proof-of-Concept studies investigating filgotinib in Sjögren`s syndrome, ankylosing spondylitis, and psoriatic arthritis.